Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-lab…

Overview of attention for article published in The Lancet HIV, May 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs: 1 blog
policy: 1 policy source

twitter: 4 X users

Citations

dimensions_citation: 72 Dimensions

Readers on

mendeley: 211 Mendeley

Summary Blogs Policy documents X Dimensions citations

So far, Dimensions has found 72 publications that cite this research output.

72

The most recent citing publications are shown below. View all 72 publications that cite this research output on Dimensions.

HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon

Article in BMC Infectious Diseases (March 2024)

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

Article in EClinicalMedicine (February 2024)

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study

Article in The Lancet Global Health (December 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.